Can new drug cocktails reawaken the immune system against melanoma?

NCT ID NCT04305041

Completed Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This trial is testing whether combining the immunotherapy drug pembrolizumab with other experimental agents can help people with advanced melanoma whose cancer has stopped responding to standard anti-PD-1 treatment. The study includes several treatment arms, each pairing pembrolizumab with a different drug, such as quavonlimab, vibostolimab, lenvatinib, or ATRA. The goal is to see if any of these combinations can shrink tumors and improve outcomes, while also monitoring safety and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Combinations of pembrolizumab with quavonlimab, vibostolimab, lenvatinib, or ATRA
What this could lead to: If successful, these combinations could offer new treatment options for people with advanced melanoma that no longer responds to current immunotherapies.
What could go wrong: This is an early-phase trial, so the combinations may not prove more effective than existing treatments and could cause additional side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autosomal dominant Parkinson disease 4 melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA

Contacts and locations

Locations

A.P.H. Paris, Hopital Saint Louis ( Site 1107)

Paris, 75010, France
CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE-Clinical Trials Unit ( Site 1865)

Port Elizabeth, Eastern Cape, 6055, South Africa
CHUV Centre Hospitalier Universitaire Vaudois ( Site 1602)

Lausanne, Canton of Vaud, 1011, Switzerland
Calvary Mater Newcastle-Medical Oncology ( Site 1404)

Waratah, New South Wales, 2298, Australia
Centre Hospitalier Lyon Sud ( Site 1102)

Pierre-Bénite, Rhone, 69495, France
Chaim Sheba Medical Center ( Site 1701)

Ramat Gan, 5265601, Israel
Duke Cancer Institute ( Site 1005)

Durham, North Carolina, 27710, United States
Fiona Stanley Hospital ( Site 1401)

Murdoch, Western Australia, 6150, Australia
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1399)

Milan, 20133, Italy
Gustave Roussy ( Site 1101)

Villejuif, Île-de-France Region, 94805, France
HaEmek Medical Center ( Site 1703)

Afula, 1834111, Israel
Hadassah Ein Karem Jerusalem ( Site 1702)

Jerusalem, 9112001, Israel
Hopital La Timone ( Site 1103)

Marseille, Bouches-du-Rhone, 13005, France
Hopital Saint Andre ( Site 1108)

Bordeaux, Gironde, 33075, France
Hôpitaux Universitaires de Genève (HUG)-Oncology ( Site 1603)

Geneva, Canton of Geneva, 1211, Switzerland
Inova Schar Cancer Institute ( Site 1011)

Fairfax, Virginia, 22031, United States
Institut Claudius Regaud ( Site 1105)

Toulouse, Haute-Garonne, 31059, France
Istituto Europeo di Oncologia ( Site 1301)

Milan, 20141, Italy
Istituto Nazionale Tumori Fondazione Pascale ( Site 1302)

Naples, 80131, Italy
Istituto Oncologico Veneto IRCCS ( Site 1355)

Padova, 35128, Italy
Martha Morehouse Tower ( Site 1020)

Columbus, Ohio, 43221, United States
Melanoma Institute Australia ( Site 1402)

Wollstonecraft, New South Wales, 2065, Australia
NYU Clinical Cancer Center ( Site 1002)

New York, New York, 10016, United States
Oregon Health & Science University ( Site 1013)

Portland, Oregon, 97239, United States
Policlinico Le Scotte - A.O. Senese ( Site 1377)

Siena, 53100, Italy
Providence Saint John's Health Center ( Site 1010)

Santa Monica, California, 90404, United States
Rambam Health Care Campus-Oncology ( Site 1704)

Haifa, 3109601, Israel
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 1022)

Baltimore, Maryland, 21287, United States
Tasman Oncology Research Pty Ltd ( Site 1403)

Southport, Queensland, 4215, Australia
The Angeles Clinic and Research Institute ( Site 1009)

Los Angeles, California, 90025, United States
UCLA Hematology & Oncology ( Site 1004)

Los Angeles, California, 90095, United States
Universitaetsspital Zuerich ( Site 1601)

Zuerich Flughafen, Canton of Zurich, 8058, Switzerland
University of Colorado, Anschutz Cancer Pavilion ( Site 1012)

Aurora, Colorado, 80045, United States
University of Pennsylvania Abramson Cancer Center ( Site 1008)

Philadelphia, Pennsylvania, 19104, United States
University of Texas MD Anderson Cancer Center ( Site 1006)

Houston, Texas, 77030, United States
West Cancer Center - East Campus ( Site 1014)

Germantown, Tennessee, 38138, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.